Document is current

Article History

Received: 6 September 2016

Accepted: 23 January 2018

First Online: 9 March 2018

Ethics approval and consent to participate

: Ethics Committee approval was not needed as the data are purely descriptive and epidemiological. Tables and include retrospective data on the results of prior routine diagnostic molecular testing; no patient level data are included and no additional procedures, tests or samples were required. All respondents were clearly informed that the information collected was to form the basis for a manuscript describing molecular testing for NSCLC in the CEE region.

: Not applicable.

: AR reports receiving grants and personal fees from AstraZeneca and MSD, honoraria for advisory board participation AstraZeneca, MSD, Novartis, Boehringer Ingelheim and personal fees and honoraria for advisory board participation and lectures from BMS, outside the submitted work. PB reports receiving honoraria from AstraZeneca, Boehringer Ingelheim, Pfizer, MSD, and Roche, and has participated at advisory boards for Boehringer Ingelheim, Pfizer, and MSD. LB reports receiving personal fees from Roche, AstraZeneca, Pfizer, Boehringer Ingelheim, outside the submitted work. TC reports receiving consulting fees from Pfizer, Boehringer Ingelheim, BMS outside the submitted work. RD reports personal fees from Pfizer, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, outside the submitted work. MG reports receiving consulting fees from Pfizer, Boehringer Ingelheim, BMS, MSD. IK reports receiving personal fees from Pfizer (participation in 2015 advisory board preparing the manuscript) related to the work under consideration. WO reports receiving honoraria or consulting fees from MSD, Boehringer Ingelheim, Pfizer and Abbott outside the submitted work. OB reports receiving consulting fees from Pfizer, Boehringer Ingelheim, BMS and MSD outside the submitted work. LP reports receiving grants from Slovak Research and Development Agency, Pfizer Slovakia, Ministry of Health Slovakia related to the work under consideration and grants from Novartis Slovakia, Takeda Slovakia, and AstraZeneca Slovakia outside the submitted work. JT reports receiving personal fees from BMS, Lilly, Pfizer, Roche, and Boehringer Ingelheim outside the submitted work. All authors report receiving financial support from Pfizer and non-financial support from SuccinctChoice Medical Communications (funded by Pfizer) related to the work under consideration.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.